Four OICR-funded studies explore transformative approaches in cancer care, leveraging patient data and samples to advance cancer research. These studies, collectively known as the CATALYST program, are designed to maximize the impact of existing research and patient contributions, pushing the boundaries of cancer detection, diagnosis, and treatment.
One study led by Dr. Neil Fleshner aims to explore the potential of a common diabetes medication, metformin, in preventing blood cancers. This builds on previous research showing that metformin impedes the growth of cells with a specific genetic mutation. By using genetic testing, the study will further investigate whether metformin can prevent blood cancers and other diseases.
Another project, led by Dr. Hon Leong and Dr. Lillian Siu, focuses on developing a blood test to predict treatment response to immunotherapy. The study builds on earlier research indicating that patients with high levels of 'endogenous retrotransposable elements' (ERE) in their tumors respond better to immune checkpoint inhibitors. The team will use the same patient samples to determine if measuring EREs in blood can predict treatment response.
Dr. Enrique Sanz Garcia and Dr. Scott Bratman are working on a blood test to identify patients at high risk of head and neck cancer recurrence. This study will utilize advanced genomic sequencing technology to detect tiny fragments of tumor DNA in blood samples, linking their presence to cancer recurrence.
Lastly, Dr. Vikas Gupta and Dr. James Kennedy are developing a system to predict treatment response in patients with rare blood cancer, myelofibrosis. They will reanalyze existing data to identify patients suitable for bone marrow transplant and determine the optimal timing for treatment.
These studies, funded by the Ontario Institute for Cancer Research (OICR), demonstrate the power of reanalyzing existing data and samples to drive innovation in cancer care. By maximizing the use of patient contributions, these projects aim to rapidly deliver life-saving discoveries and improve the lives of cancer patients.
Dr. David Cescon, Scientific Director of OICR's Clinical Translation research theme, emphasizes the importance of honoring patient contributions and maximizing research opportunities. Cancer patients, through their time, insights, and samples, are critical partners in advancing cancer research and care.
Vivian Simbul Sim, a cancer survivor and patient partner, highlights the desire of patients to see their participation make a difference. These studies, she says, are a testament to the impact of patient involvement in cancer research.
The CATALYST program, supported by the Ontario government, showcases the commitment to driving life-saving discoveries in cancer detection, diagnosis, and treatment. By staying ahead of cancer, these studies contribute to the overall goal of improving health outcomes and saving lives.
